


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
BEVACIZUMAB INJECTION APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has obtained drug registration certificate from the National Medical Products Administration of China for the biosimilar Bevacizumab Injection (Anbeisi) researched and developed by the Group, approved for the treatment of three indications, namely metastatic colorectal cancer, recurrent glioblastoma, and advanced, metastatic or recurrent non-small cell lung cancer.

Bevacizumab is a vascular endothelial growth factor (**VEGF**) inhibitor. The Bevacizumab researched and developed by the Group is a recombinant humanised IgG1 monoclonal antibody which can specifically bind to VEGF to reduce tumour neovascularisation and restrict tumour growth, while normalising tumour vessels, improving vascular permeability and increasing the effective drug concentration in tumour tissues, thus exerting its anti-tumour effects. Bevacizumab was developed in compliance with the requirements of the Technical Guidelines for R&D and Evaluation of Biosimilars. A comprehensive comparative study was conducted on nine quality attributes, namely primary structure, advanced structure, glycan profiling, granules, general attributes, product-related substances and impurities, process-related impurities, biological activity and stability, in relation to commercially available reference drugs. The results of the study showed that Anbeisi was similar to the commercially available reference drug. The similarity between Anbeisi and the commercially available product has been further validated through clinical trial studies. Meanwhile, the formulation optimisation study has resulted in the selection of a formulation that is more suitable for protein stability, resulting in a product with lower polymer impurities and better stability.

Bevacizumab, as a broad-spectrum anti-tumour drug, has a high market potential. The launch of the Group's Anbeisi will further enhance the accessibility of Bevacizumab for the benefit of patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 3 March 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald